Gregory Worrell, MD
Epilepsy · Rochester, MNNPI 1396725297
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (37.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Neuropace, Inc. at 46.6% of the total. Reporting peaked in 2024 at $6,370 and has fallen 97.3% since, to $172 in 2025.
Across 18 payments — averaging $598.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuropace, Inc.$5K
- Medtronic$4K
- Livanova USA, Inc.$1K
- Neurelis, Inc.$172
- Boston Scientific$26
- GT Medical Technologies, Inc$13
Across 11 payments — averaging $9453.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$104K
What the payments were for
- Consulting fees$3,60033%
- Speaking & faculty fees$4,05038%
- Travel & lodging$2,49223%
- Food & beverage$6366%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuropace, Inc. | 6 | $5,021 |
| Medtronic | 3 | $4,199 |
| Livanova USA, Inc. | 5 | $1,348 |
| Neurelis, Inc. | 2 | $172 |
| Boston Scientific | 1 | $26 |
| GT Medical Technologies, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RNS Neurostimulator Kit$4,969
- ACTIVA$4,185
- VNS Therapy$1,205
- VALTOCO$133
How this compares
Too few epilepsy providers in Minnesotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 75 | $127,885 |
| VimpatLacosamide | 26 | $58,670 |
| LamictalLamotrigine | 16 | $40,202 |
| KeppraLevetiracetam | 13 | $33,520 |
| Carbamazepine ErCarbamazepine | 15 | $5,362 |
| Divalproex Sodium | 35 | $4,531 |
| Levetiracetam | 65 | $3,081 |
| Lamotrigine | 81 | $2,872 |
| Zonisamide | 14 | $1,134 |
| Lacosamide | 13 | $541 |
| Topiramate | 19 | $158 |
Paid to pharmacies, not to this prescriber.
Other epilepsy in Rochester
- Elaine WirrellRochester$160K
- Katherine NickelsRochester$23K
- Brian LundstromRochester$9K
- Kelsey SmithRochester$3K
- Christopher SanfilippoRochester$1K
- David BurkholderRochester$714
- Nicholas GreggRochester$312
- Anthony FineRochester$231
- Gregory CascinoRochester$203
- Hicham DabajaRochester$195
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.